Leonard A. Lauder Decides Not to Stand for Re-Election to The Estée Lauder Companies Board of Directors
24.8.2023 23:25:00 EEST | Business Wire | Press release
The Estée Lauder Companies announced today that Chairman Emeritus Leonard A. Lauder has informed the Company of his decision not to stand for re-election to the Company’s Board of Directors (the “Board”) at the annual meeting in November. Leonard Lauder remains Chairman Emeritus of the Company. Pursuant to the stockholders’ agreement among Lauder family members and the Company, Leonard Lauder has the right to designate two directors of the Company. In addition to his son William P. Lauder, who serves as Executive Chairman, Leonard Lauder has designated his son Gary M. Lauder to serve on the Board. The Board has nominated Gary Lauder and will include his name among the nominees for election at the Company’s annual meeting in November. Gary Lauder is the Managing Director of Lauder Partners LLC, a Silicon Valley-based venture capital firm. He has been a venture capitalist since 1985, investing in over 150 private companies. Gary serves on the Board of Governors of Alzheimer’s Drug Discovery Foundation and holds a BA in International Relations from the University of Pennsylvania; a BS in Economics from the Wharton School; and an MBA from the Stanford Graduate School of Business. Gary has periodically attended the Company’s Board meetings over the years as an invited observer, which has provided him with a long-term view of the Company.
Leonard Lauder formally joined The Estée Lauder Companies in 1958 and served as President from 1972 to 1995 and as Chief Executive Officer from 1982 to 1999. He became Chairman of the Board in 1995 and served in that role through June 2009, until he was appointed Chairman Emeritus for the Company. As Chairman Emeritus, Leonard Lauder provides his advice and counsel on a variety of business topics including brand building, marketing, and understanding the global luxury consumer. He continues to play an active role as “Chief Teaching Officer,” educating leaders throughout the Company with his brand symposiums and through speaking engagements with global employees.
“My father envisioned and helped drive the growth and expansion of our Company from an iconic single brand to the global, brand-building powerhouse it is today. We’ve never wavered from his vision of being a home for the best brands and best people, all of whom are united in delivering high-quality, prestige beauty products and high-touch service and experiences, while maintaining our unique, values-driven culture,” said William P. Lauder, Executive Chairman. “It has been an incredible honor and privilege to have worked with and learned from my father over the years. I look forward to continuing to learn from him and know his passion for this industry, this Company, our employees and our consumers is as strong as ever.”
“It has been an honor and privilege to serve on the Board of the Company my mother and father created over 75 years ago,” said Leonard Lauder. “This Board is one of the best in the business. I feel confident that the Company’s leadership and Board will continue to guide our strategy to deliver long-term growth. Additionally, I continue to believe in the success of our Company through the skillful and thoughtful management by William, Fabrizio, and the entire leadership team. The nomination of Gary to the Board further reflects my family’s long-term stewardship, and our support of the vision, values, and people who will drive the Company’s future success. As Chairman Emeritus of the Company, I’m looking forward to continuing my work as advisor and “Chief Teaching Officer,” serving what I believe to be the best Company in the world.”
“On behalf of the Board, I share my deep admiration and appreciation to Leonard for his invaluable contributions to the Company as an officer and as a member of the Board. He is a visionary whose creative thinking is unmatched in the industry. His innovative insights will continue to serve as inspiration for us all,” said Charlene Barshefsky, the Company’s Presiding Director.
In addition to his activities with The Estée Lauder Companies, Leonard Lauder is extremely involved in the worlds of education, art, politics, and philanthropy. He is a Charter Trustee of the University of Pennsylvania and a founding member of the Board of Governors of its Joseph H. Lauder Institute of Management and International Studies. Leonard Lauder became a Trustee of the Whitney Museum of American Art in New York City in 1977 and currently serves as its Chairman Emeritus. He is Co-Founder and Co-Chairman of the Alzheimer’s Drug Discovery Foundation; Honorary Chairman of the Breast Cancer Research Foundation; a member of the Council on Foreign Relations; a Trustee of the Aspen Institute; and a member of the President’s Council of Memorial Sloan-Kettering Hospital. Leonard Lauder also served on the Advisory Committee for Trade Negotiations under President Ronald Reagan. Among his honors, he has been named an Officier de la Légion d’Honneur by France and recognized by the U.S. Navy Supply Corps Foundation with its Distinguished Alumni Award, was the 2013 recipient of the Palazzo Strozzi Renaissance Man of the Year Award, and was named a 2014 Living Landmark by the New York Landmarks Conservancy.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-C
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230824369024/en/
Contact information
Investors:
Rainey Mancini
rmancini@estee.com
Media:
Jill Marvin
jimarvin@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne to Open Major New Manufacturing Facility to Meet Rapidly Growing Global Demand11.2.2026 14:00:00 EET | Press release
Echodyne, the radar platform company, today announces a major near-term expansion in its advanced radar production capacity. Echodyne’s new 86,350-square-foot facility will provide enough manufacturing and warehouse space to produce and ship more than 30,000 radars per year. The company’s modular manufacturing approach allows production capacity to flex to match varying demand across product lines as well as seamlessly introducing new product lines and capabilities. The investment reflects Echodyne’s continued commitment to: enhancing security and safety as UxS become ubiquitous on the battlefield and in society in general, staying ahead of the accelerating demand in the U.S. and in Allied countries around the globe, and strengthening America’s defense industrial base. Counter-UAS (C-UAS), beyond visual line of sight (BVLOS) operations for drone-as-first-responders (DFR), force protection, border security, and on-the-move (OTM) are among the applications and capabilities driving accele
Americhem Recognized Among Top 5% Globally for Sustainability Performance with EcoVadis Gold Rating11.2.2026 14:00:00 EET | Press release
Americhem, a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, has earned the EcoVadis Gold rating, placing the company among the top 5% of organizations assessed globally for sustainability performance in their sector. EcoVadis is one of the world’s most widely used business sustainability assessment platforms, evaluating companies across Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. The Gold rating reflects not only the presence of sustainable policies but also the robustness of management systems, documentation, and implementation practices, as evaluated by EcoVadis across Americhem’s global operations. The EcoVadis Gold rating follows Americhem’s prior Silver ratings in recent years and reflects continued strengthening of environmental stewardship, governance, and management systems across the organization. “This recognition reflects how our teams run the bus
4Moving Biotech Announces the Closing of a €12 Million Financing to Advance a First-in-Class DMOAD in Knee Osteoarthritis11.2.2026 13:30:00 EET | Press release
4Moving Biotech (4MB), a clinical-stage biotechnology company and a spin-off of 4P-Pharma, developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, today announced the closing of a €12 million financing, completed through a structured and coordinated funding process. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209500141/en/ Francis Berenbaum (Left) Luc Boblet, Revital Rattenbach, Jérôme Vailland (Right) This financing was secured from a pool of private investors and family offices, who chose to reinforce their commitment by investing directly at the subsidiary level in 4MB. The round includes a combination of equity and loans, reflecting a flexible capital structure aligned with long-term value creation. This closing forms a natural continuum following the €7.6 million France 2030 i-Démo grant announced last year, and the very recent transatlantic extension of the INFLAM-MOTION
Agentic AI Consulting: Sia Accelerates Its Development with More Than 400 Agents on Its Agent Store11.2.2026 13:17:00 EET | Press release
Sia, an international consulting group specializing in strategy, management, and AI, has reached a milestone in its Agentic AI journey. Born in the digital era, the firm now leverages the expertise of more than 3,000 consultants in 19 countries to help organizations scale AI-driven transformation. From GenAI to an Agent Store for All Industries and Functions After unveiling its Generative AI platform to clients in June 2023, the firm announced the launch of its Agent Store in September 2025. Built on a learn-by-design approach, Sia’s Agent Store grew from 50 AI agents to over 400 available for direct consultation, with over a dozen Minimum Viable Products ready for demonstration. Originally introduced as SiaGPT, the platform is now accessible via siagents.ai, reflecting the transition from custom GPTs to fully agentic services. Sia’s AI agents cover a wide range of industries such as Finance, Energy, Public Sector, Healthcare, and Retail and Consumer Goods, and address all corporate fu
BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 2611.2.2026 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics thro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
